- Home
- QUAD vs ENGN Comparison
QUAD vs ENGN Comparison
Compare QUAD & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUAD
- ENGN
- Stock Information
- Founded
- QUAD 1971
- ENGN 1999
- Country
- QUAD United States
- ENGN Canada
- Employees
- QUAD N/A
- ENGN N/A
- Industry
- QUAD Publishing
- ENGN
- Sector
- QUAD Consumer Discretionary
- ENGN
- Exchange
- QUAD Nasdaq
- ENGN Nasdaq
- Market Cap
- QUAD 287.7M
- ENGN 297.7M
- IPO Year
- QUAD 2010
- ENGN N/A
- Fundamental
- Price
- QUAD $5.17
- ENGN $3.94
- Analyst Decision
- QUAD Strong Buy
- ENGN Buy
- Analyst Count
- QUAD 2
- ENGN 7
- Target Price
- QUAD $10.15
- ENGN $23.29
- AVG Volume (30 Days)
- QUAD 237.6K
- ENGN 45.7K
- Earning Date
- QUAD 04-29-2025
- ENGN 06-13-2025
- Dividend Yield
- QUAD 4.38%
- ENGN N/A
- EPS Growth
- QUAD N/A
- ENGN N/A
- EPS
- QUAD N/A
- ENGN N/A
- Revenue
- QUAD $2,672,200,000.00
- ENGN N/A
- Revenue This Year
- QUAD N/A
- ENGN N/A
- Revenue Next Year
- QUAD N/A
- ENGN N/A
- P/E Ratio
- QUAD N/A
- ENGN N/A
- Revenue Growth
- QUAD N/A
- ENGN N/A
- 52 Week Low
- QUAD $4.06
- ENGN $3.50
- 52 Week High
- QUAD $9.13
- ENGN $16.62
- Technical
- Relative Strength Index (RSI)
- QUAD 44.74
- ENGN 33.51
- Support Level
- QUAD $4.99
- ENGN $3.77
- Resistance Level
- QUAD $5.27
- ENGN $4.32
- Average True Range (ATR)
- QUAD 0.24
- ENGN 0.38
- MACD
- QUAD 0.04
- ENGN 0.03
- Stochastic Oscillator
- QUAD 52.91
- ENGN 38.46
About QUAD Quad Graphics Inc
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.